Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 9/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | LPL | P06858 | 2/20 | 0.37 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.37 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | CA6 | P23280 | 1/20 | 0.35 |
| ▸ | CA5A | P35218 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.35 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12050488 | 0.77 | ENPP2 (0.48) | ENPP2KDM4EMGLLCA1CA2 | |
| SCHEMBL133330 | 0.75 | ENPP2 (0.50) | ENPP2KDM4EALDH1A1MGLLCA1 | |
| SCHEMBL8975041 | 0.73 | ACHE (0.44) | ALDH1A1 | |
| SCHEMBL13913369 | 0.72 | ALDH1A1 (0.39) | ALDH1A1CA1CA2 | |
| SCHEMBL14285751 | 0.72 | EGFR (0.39) | KDM4EALDH1A1 | |
| SCHEMBL23912437 | 0.70 | ENPP2 (0.45) | ENPP2KDM4EALDH1A1MGLLCA1 | |
| SCHEMBL3110223 | 0.70 | ENPP2 (0.45) | ENPP2KDM4EALDH1A1MGLLCA1 | |
| SCHEMBL29951972 | 0.70 | ENPP2 (0.46) | ENPP2KDM4EALDH1A1MGLLCA1 | |
| SCHEMBL852507 | 0.70 | LPL (0.46) | ENPP2KDM4EALDH1A1MGLLCA1 | |
| SCHEMBL29956472 | 0.70 | ENPP2 (0.45) | ENPP2KDM4EALDH1A1MGLLCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212127-A1 | LIVER X RECEPTOR (LXR) MODULATORS | ELLORA THERAPEUTICS, INC. | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212127-A1 | LIVER X RECEPTOR (LXR) MODULATORS | NR1H2, NR1H3, NR1H4 | ENPP2 280/4885KDM4E 3489/4885ALDH1A1 2323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.